Alerta

呕吐毒素致断奶仔猪肠道铁死亡的抑制剂及制备方法

Absstract of: CN120478304A

本发明涉及畜牧技术领域，尤其涉及一种呕吐毒素致断奶仔猪肠道铁死亡的抑制剂及制备方法，本发明整合铁螯合剂(去铁胺，DFO)、GPX4激活剂(硒甲硫氨酸，SeMet)及抗炎成分(姜黄素、黄芪多糖、双氢青蒿素)，覆盖铁蓄积、GPX4失活、脂质过氧化等铁死亡三大核心通路；同时，采用pH敏感型壳聚糖‑海藻酸钠纳米颗粒对以上成分进行包被，使其能够过胃，避免受到胃酸的破坏，确保药物在肠道的碱性环境中精准释放，从而提高药物的利用率；并且，硒甲硫氨酸、姜黄素、黄芪多糖、双氢青蒿素均为天然来源，可以避免化学药物残留风险，可作为饲料添加剂应用于断奶仔猪当中。

METHOD FOR PRODUCING METAL OXIDE NANO-PARTICLES, AND METAL OXIDE NANO-PARTICLES

Absstract of: US2025256978A1

The present invention enables us to achieve both further fine particle size reduction and uniformity of particle size distribution of metal oxide nanoparticles.The present invention is a method for producing metal oxide nanoparticles that consists of a process for obtaining metal oxide nanoparticles by mixing a supercritical, subcritical, or gas phase aqueous material and an organometallic complex solution, wherein the mixing time is controllable within the range of 0.015 s to 380 s and the diameter of at least one of the average primary particle diameter or the crystallite diameter of the nanoparticles can be controlled within the range of 1.0 nm to 9.0 nm, and the coefficient of variation of the diameter can be controlled within 0.5 nm or less by controlling the mixing time. The resulting nanoparticles encompass metal elements capable of forming organometallic complexes. Additionally, the organic molecules are strongly bonded to the most unstable surface.

HYBRID NANOFIBROUS MAT AND METHOD OF MAKING SAME

Absstract of: WO2025166401A1

There is provided a hybrid nanofibrous mat comprising electrospun nanofibers formed by electrospinning of a polymer mix and porous silica capsules dispersed throughout the electrospun nanofibers during the electrospinning, the porous silica capsules having a hydrophobic liquid core containing an active. There is also provided a method of producing a hybrid nanofibrous mat comprising providing porous silica capsules having a hydrophobic liquid core containing an active, forming an electrospinning solution comprising the porous silica capsules and an electrospinning polymer mix, homogenising the electrospinning solution to fully disperse the porous silica capsules, and electrospinning the electrospinning solution to form the hybrid nanofibrous mat.

IMPROVED NANOCARRIER MANUFACTURING

Absstract of: US2025256248A1

An apparatus may be for producing nanocarriers and/or nanoformulations. A process may be for producing a nanocarrier and/or a nanoformulation with this apparatus. According to the preparation, a first liquid phase and a second liquid phase are mixed first to give a primary mixture using a static mixer. In a subsequence mixing step the primary mixture is diluted with a third liquid. An aspect of apparatus may be that the arrangement of the static mixer inside a linear pipe conducting a third liquid phase. Thus, the primary mixture exiting the mixer is instantaneously diluted with to give secondary mixture. The volume flow of the third mixture is chosen larger than the volume flow of the primary mixture. By these measures, nanocarriers with improved morphology and homogeneity are produced. Encapsulation efficiency was enhanced as well.

METHODS AND COMPOSITIONS RELATED TO TRNA THERAPEUTICS FOR TREATING VISION LOSS

Absstract of: US2025257354A1

Provided herein are compositions and methods related to tRNA therapeutics for treating vision loss and blindness.

DRUG-DELIVERY NANOPARTICLES AND TREATMENTS FOR DRUG-RESISTANT CANCER

Absstract of: US2025255978A1

Disclosed herein are compositions comprising nanoparticles comprising a carrier polypeptide and a double-stranded oligonucleotide, wherein the carrier polypeptide comprises a cell-targeting segment, a cell-penetrating segment, and an oligonucleotide-binding segment; and wherein the molar ratio of the carrier polypeptide to the double-stranded oligonucleotide in the nanoparticle composition is less than about 6:1, along with methods of making and using such nanoparticles. Further described are methods of treating a subject with a cancer, such as a chemotherapeutic drug resistant cancer comprising administering to the subject a composition comprising nanoparticles, the nanoparticles comprising a carrier polypeptide comprising a cell-targeting segment, a cell-penetrating segment, and an oligonucleotide-binding segment; a double-stranded oligonucleotide bound to the oligonucleotide-binding segment; and a chemotherapeutic drug bound to the double-stranded oligonucleotide. Also described are pharmaceutical compositions, articles of manufacture, and kits comprising the described nanoparticles.

MNO NANOMATERIAL BASED INHIBITORS OF INFLAMMATION AND CANCER METASTASIS

Absstract of: US2025255984A1

The anionic manganese oxide nanoparticle nucleic acid scavengers are biodegradable anionic scavengers with low cytotoxicity, which are able to scavenge (bind) cell-free nucleic acids (e.g., extracellular ssRNA, dsRNA, and unmethylated DNA), providing treatment for various medical conditions. The main component of the scavenger is manganese oxide, which may be synthesized by using a manganese compound (e.g., manganese acetate) and an acid (e.g., tannic acid) at high temperature (e.g., 100-150° C.). Synthesis may be performed by mixing a manganese compound and an acid in water forming a mixture, which is stirred, heated, and allowed to cool. The anionic manganese oxide nanoparticles are extracted from the cooled mixture. The typical size of the resultant nanomaterials ranges from 30 to 100 nm; the zeta potential of the as-prepared nanomaterials is about −20 mV. The nanoparticles have various uses, including administration to a subject to treat inflammation or to treat cancer.

COMPLEX

Absstract of: US2025255974A1

An object is to provide a technique that improves the poor solubility of a compound of formula (1) in water and further suppresses the cytokine excessive release action and bone marrow toxicity of the compound of formula (1). This object is achieved by a complex comprising a modified polysaccharide containing a hydrophobic group, and a compound represented by formula (1).

Multifunctional Nanoparticles and Uses in Managing Cancer and Cardiovascular Diseases

Absstract of: US2025255829A1

This disclosure relates to nanoparticles comprising a cardiovascular agent, a PD-L1 binding agent on the surface, and optionally an anticancer agent. In certain embodiments, the cardiovascular agent is an inhibitor of cholesterol acyltransferase such as avasimibe. In certain embodiments, the nanoparticles comprise a hyaluronic acid core. In certain embodiments, this disclosure relates to methods of treating or preventing cancer and/or atherosclerosis, or other cardiovascular disease by administering an effective amount of nanoparticles disclosed herein to a subject in need thereof.

ICE-BASED LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF MRNA

Absstract of: US2025255971A1

The present invention provides, among other things, compositions and methods of formulating nucleic acid-containing nanoparticles comprising no more than three distinct lipids components, one distinct lipid component being a sterol-based cationic lipid. In some embodiments, the present invention provides compositions and methods in which the lipid nanoparticles further comprise helper lipids and PEG-modified lipids. The resulting formulation comprises a high encapsulation percentage for nucleic acids.

Peptide-Protected Gold Nanocluster and Uses Thereof

Absstract of: US2025255962A1

A gold nanocluster of the formula Au22(Lys-Cys-Lys)16, wherein Lys-Cys-Lys is lysine-cysteine-lysine, and methods for synthesis, are provided. The gold nanocluster effectively produces Type I ROS and functions as photosensitizer, and has utility in applications such as, but not limited to, biomedical applications and photocatalysis. The gold nanocluster may be useful in photodynamic therapy (PDT) and as a radiosensitizer in cells and tissues for treating diseases such as certain cancers.

PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS

Absstract of: US2025255850A1

Method and compositions that comprise an agent that reduces nNOS activity and uses thereof in the treatment of a disease or condition in which a beneficial clinical effect is achieved by reduction in neuronal nitric oxide synthase (nNOS) activity are provided.

FORMULATIONS COMPOSED OF CATIONIC LIPIDS AND POLY(LACTIC-CO-GLYCOLIC ACID) FOR THE DELIVERY OF POLYNUCLEOTIDES INTO CELLS

Absstract of: US2025255817A1

A nanoprecipitation or nanoemulsion method forms a polynucleotide delivery particle, wherein the polynucleotide delivery particle contains at least one poly(lactic-co-glycolide), at least one cationic surfactant, at least one polynucleotide, and optionally at least one additive, wherein the poly(lactic-co-glycolide) has a weight average molecular weight Mw of 1000 to 9500 g/mol measured via gel permeation chromatography using polystyrene standards and chloroform. The polynucleotide delivery particle as an additional component in an oral drug delivery composition or a parenteral drug delivery composition supports the beneficial characteristics of the application as a medicament.

POLYSULFIDE MICROPARTICLES AND USES THEREOF

Absstract of: US2025255816A1

Disclosed herein are polysulfide microparticles that include a varying monomer composition. The monomer composition can control properties of the microparticles, such as crystallinity, which can aid in the production and stability of the microparticles. An example microparticle includes a polymer derived from monomers of propylene sulfide (PS) and ethylene sulfide (ES). The microparticles disclosed herein can be useful in drug delivery applications, such as treating inflammatory diseases. Also disclosed are methods of making the polysulfides and methods of making the microparticles.

LYOPHILIZED LIPID NANOPARTICLES AND METHODS OF THEIR USE

Absstract of: US2025255828A1

The invention is directed to the field of therapeutic formulations, in particular to lyophilization of a therapeutic cargo molecule, such as RNA. The invention provides a method for lyophilization of a molecule. The present disclosure further describes a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine, a therapeutic and a kit or kit of parts. Moreover, the disclosure herein provides a novel lyophilization excipient that protects the composition from degrading when, for example, lyophilizing RNA. The use of the inventive method further includes the manufacture of a composition that can be used after lyophilization with equivalent therapeutic effect and composition integrity.

NUCLEIC ACIDS ENCODING A CONSTITUTIVELY-ACTIVE CYCLIC GMP-AMP SYNTHASE AND IMMUNOGENIC DELIVERY VEHICLES FOR SAME

Absstract of: US2025255815A1

The present disclosure relates to compositions for expression of a constitutively-active cyclic GMP-AMP synthase in cells of a mammalian subject and uses thereof for enhancing immunogenicity of mRNA vaccines. The mRNA may be encapsulated in a lipid nanoparticle (LNP) or may be complexed with a lipid (RNA-Lipoplex). The present disclosure also relates to compositions further comprising one or both of a lysophosphatidylcholine (LPC) compound and a pathogen recognition receptor agonist.

VAPOR PHASE COATING TECHNOLOGY FOR PHARMACEUTICAL ABUSE DETERRENT FORMULATIONS

Absstract of: US2025255831A1

A method of preparing an abuse deterrent pharmaceutical composition having a drug-containing core enclosed by one or more metal oxide materials is provided. The method includes the sequential steps of (a) loading the particles comprising the drug into a reactor, (b) applying a vaporous or gaseous metal precursor to the particles in the reactor, (c) performing one or more pump-purge cycles of the reactor using inert gas, (d) applying a vaporous or gaseous oxidant to the particles in the reactor, and (e) performing one or more pump-purge cycles of the reactor using inert gas. This produces an abuse deterrent pharmaceutical composition comprising a drug containing core enclosed by one or more metal oxide materials.

POLYMER-LIPID NANOCOMPLEX FOR ENHANCED AQUEOUS SOLUBILISATION AND ABSORPTION OF HYDROPHOBIC ACTIVE COMPOUNDS

Absstract of: US2025255825A1

The current invention relates to a polymer-lipid nanocomplex for enhanced aqueous solubilisation and absorption of hydrophobic active compounds, a process for producing such a nanocomplex, and to methods of use of such a nanocomplex.

NANOGEL PLATFORM TECHNOLOGY FOR LONG-TERM BIOLOGICS THERAPY

Absstract of: US2025255808A1

Biologics, including peptides, proteins, antibodies, nucleic acids (DNA and RNA), oligonucleotides, vaccines, or complex combinations of these substances, are important for treating various types of diseases and tissue and organ regeneration. However, biologics are not stable and have short half-lives, making effective delivery to patients difficult. Therefore, there is an unmet need in the art to increase the stability and half-lives of biologics for long-term bioavailability, therapy, treatment and repair. This invention provides a nanogel platform technology that can load biologics in aqueous solution with high loading efficiency without using any organic solvent and also sustain the release of active biologics in the body for more than 2 months.

BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELS

Absstract of: US2025255830A1

A method of treatment or prevention of HIV and other viral infection comprising the administration of a biopolymer-based hydrogel nanoparticles and/or microparticles. In preferred embodiments, the particles comprise chitosan, hydroxyethyl cellulose (HEC), and linseed oil polyol. These biopolymer-based hydrogel nanoparticles and/or microparticles are antiviral agents that can be employed alone or in combination with other drugs for treatment of the viral infection. Further, the pre-treatment with the particles is highly effective at inhibiting viruses. Therefore, this antiviral biopolymer-based hydrogel nanoparticles and/or microparticles may also be employed as a prophylactic.

IMPROVED PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES

Absstract of: AU2025208550A1

The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process for enhanced encapsulation of messenger RNA (mRNA) in lipid nanoparticles comprising a step of heating the mRNA-encapsulated lipid nanoparticles in a drug product formulation solution. The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process for enhanced encapsulation of messenger RNA (mRNA) in lipid nanoparticles comprising a step of heating the mRNA-encapsulated lipid nanoparticles in a drug product formulation solution. ul h e p r e s e n t i n v e n t i o n p r o v i d e s a n i m p r o v e d p r o c e s s f o r l i p i d n a n o p a r t i c l e f o r m u l a t i o n u l a n d m e n c a p s u l a t i o n n s o m e e m b o d i m e n t s , t h e p r e s e n t i n v e n t i o n p r o v i d e s a p r o c e s s f o r e n h a n c e d e n c a p s u l a t i o n o f m e s s e n g e r ( m ) i n l i p i d n a n o p a r t i c l e s c o m p r i s i n g a s t e p o f h e a t i n g t h e m - e n c a p s u l a t e d l i p i d n a n o p a r t i c l e s i n a d r u g p r o d u c t f o r m u l a t i o n s o l u t i o n

METHOD FOR SYNTHESIZING ZEOLITE NANOPARTICLES IN A SALINE PHOSPHATE BUFFER AND ASSOCIATED NANOPARTICLES, SUSPENSIONS AND PHARMACEUTICAL COMPOSITION

Absstract of: AU2024248582A1

The present invention relates to a method for synthesizing nanoparticles consisting of or comprising at least one zeolite nanocrystal according to which: - a first composition/solution 1 containing an aluminum source and a source of an ion of an alkali metal M, in particular K, is prepared; a second composition/solution 2 comprising a silicon source and a source of an ion of an alkali metal M, in particular K, is prepared, said compositions/solutions 1 and 2 being free of any organic structuring agent; - the two compositions/solutions 1 and 2 are mixed; - the mixture is crystallized; and - said nanoparticles thus formed are optionally separated. According to the invention, said first composition/solution 1 and said second composition/solution 2 are both constituted of said source and of the aqueous saline phosphate buffer. The present invention also relates to colloidal suspensions of the nanoparticles obtained and to a pharmaceutical composition containing said nanoparticles.

CLEAVABLE LINKER-CONTAINING IONIZABLE LIPIDS AND LIPID CARRIERS FOR THERAPEUTIC COMPOSITIONS

Absstract of: TW202438045A

The present disclosure relates to a lipid compound of formula (AL-GI):, having various cleavable linkers defined by the variables Z1 and Z2. The present disclosure also relates to a lipid carrier or lipid nanoformulation employing the lipid compound, and the use of the lipid compound in a pharmaceutical composition as well as for a method of delivering a therapeutic agent.

IONIZABLE CATIONIC COMPOUND

Absstract of: AU2024217713A1

Novel ionizable lipid compounds of Formula I-Het, Formula I and Formula II are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.

IONIZABLE CATIONIC COMPOUND

Nº publicación: AU2024218499A1 14/08/2025

Applicant:

SEQIRUS INC
SEQIRUS INC

Absstract of: AU2024218499A1

Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.